Trabectedin for the treatment of advanced soft tissue sarcoma

  • Technology appraisal guidance
  • TA185
  • Published: 
  • Last updated: 
Download guidance (PDF)

Appendix B: Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by the School of Health and Related Research (ScHARR), University of Sheffield:

  • Simpson EL, Rafia A, Stevenson MD, et al. Trabectedin for the treatment of advanced metastatic soft tissue sarcoma,
    May 2009

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to give their expert views. Organisations listed in I and II also have the opportunity to appeal against the final appraisal determination.

I) Manufacturer/sponsor:

  • PharmaMar

II) Professional/specialist and patient/carer groups:

  • British Sarcoma Group

  • Cancer Research UK

  • Rarer Cancers Forum

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians – Medical Oncology Joint Special Committee

  • Royal College of Radiologists

  • Sarcoma UK

III) Commentator organisations (did not provide written evidence and without the right of appeal):

  • Department of Health

  • Welsh Assembly Government

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Institute of Cancer Research

  • MRC Clinical Trials Unit

  • NHS Quality Improvement Scotland

C. The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer/sponsor consultees and commentators. They gave their expert personal view on trabectedin by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD:

  • Professor Ian Judson, nominated by the Royal College of Physicians, on behalf of the National Cancer Research Institute, the Royal College of Physicians, the Royal College of Radiologists, the Association of Cancer Physicians and the Joint Collegiate Council for Oncology – clinical specialist.

  • Stella Pendleton, nominated by the Rarer Cancers Forum – patient expert.

  • Roger Wilson, nominated by Sarcoma UK – patient expert.